Using eCD4-Ig to prevent and treat HIV in pregnant women
eCD4-Ig for preventing and treating obstetric HIV infection
This study is looking at a new treatment called eCD4-Ig to help prevent and treat HIV in pregnant and new moms in sub-Saharan Africa, aiming to find a safe and effective option for women during this important time when they are at higher risk for the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10844404 on NIH RePORTER |
What this research studies
This research investigates the use of eCD4-Ig, an innovative antibody-like HIV entry inhibitor, to prevent and treat HIV infections in pregnant and postpartum women in sub-Saharan Africa. The study aims to address the heightened risk of HIV acquisition during pregnancy and breastfeeding, a critical period when women are often excluded from clinical trials. By exploring the safety and effectiveness of eCD4-Ig, the research seeks to provide a new therapeutic option for women who are disproportionately affected by HIV. Participants may receive eCD4-Ig to assess its ability to neutralize HIV and improve health outcomes during these vulnerable stages.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant or postpartum women living in sub-Saharan Africa who are at risk of HIV infection.
Not a fit: Patients who are not pregnant or breastfeeding, or those who do not reside in sub-Saharan Africa, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new preventive and therapeutic option for pregnant and breastfeeding women at risk of HIV infection.
How similar studies have performed: While the approach of using eCD4-Ig is novel, similar strategies targeting HIV prevention in high-risk populations have shown promise in other contexts.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Martins, Mauricio de Aguiar — University of Florida
- Study coordinator: Martins, Mauricio de Aguiar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.